Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L04AA35Orphan Medicine

Begedina(begelomab)

Graft vs Host Disease;Hematopoietic Stem Cell Transplantation

Marketing Authorisation Holder: Adienne S.r.l. S.U.

Indication

Treatment of graft-versus-host disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Begedina — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.